Pharmacology of lorcainide.

@article{Keefe1984PharmacologyOL,
  title={Pharmacology of lorcainide.},
  author={D. Keefe},
  journal={The American journal of cardiology},
  year={1984},
  volume={54 4},
  pages={
          18B-21B
        }
}
  • D. Keefe
  • Published 1984
  • Medicine
  • The American journal of cardiology
    • Lorcainide is a new type 1 antiarrhythmic drug that is well absorbed orally, with bioavailability increasing with both dose and continued administration. It is metabolized through the liver, and patients with significant liver disease will require dosage reduction. The drug has an active metabolite, norlorcainide, whose activity is similar to that of lorcainide but whose half-life is 26 hours instead of 8 for the parent compound. The levels of this metabolite are nearly twice those of… CONTINUE READING
    View on PubMed
    doi.org
    10 Citations

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

    10 Citations
    Citation Type

    Citation Type

    Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.
    • 3
    Part III: Class IC Antiarrhythmic Drugs—A Review of Their Pharmacokinetics, Electrophysiology, Efficacy, and Toxicity*
    • 4
    Recent antiarrhythmic drugs.
    • 13
    Initial and long-term outpatient experience with lorcainide for suppression of malignant and potentially malignant ventricular arrhythmias.
    • 6
    Newer antiarrhythmic drugs.
    • 16
    Comparison in vitro of the electrophysiological effects of lorcainide and its metabolite norlorcainide.
    • E. Carmeliet
    • Biology, Medicine
    • European journal of pharmacology
    • 1987
    Class I antiarrhythmic drug effects on ouabain binding to guinea pig cardiac Na+ -K+ ATPase.
    • 8
    Treatment of cardiac arrhythmias during pregnancy.
    • 77
    4-Substituted and 1,4-Disubstituted Piperidines
    Neurological complications of cardiovascular therapy.
    • 4

    References

    SHOWING 1-10 OF 21 REFERENCES
    Pharmacokinetics of Lorcainide in Man: A New Antiarrhythmic Agent
    • 50
    Lorcainide; I. Saturable presystemic elimination
    • 57
    Lorcainide (R 15 889), a first review.
    • 19
    Disposition and antiarrhythmic effect of lorcainide.
    • 29
    Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
    • 13
    Lorcainide; II. Plasma concentration‐effect relationship
    • 60
    Alterations in the disposition of differently cleared drugs in patients with cirrhosis
    • 32
    Lorcainide disposition kinetics in arrhythmia patients
    • 26
    Haemodynamic reactions after intravenous injection of lorcainide hydrochloride in acute myocardial infarction.
    • 10
    Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
    • 24
    • PDF